|
|
 |
|
Viewing report
|
|
|
|
Premium Company Profile Novavax
Datamonitor, Oct 2007, Pages: 46
Introduction
Novavax is a biopharmaceutical company focused on developing vaccines against the H5N1, H9N2 and other subtypes of avian influenza with pandemic potential as well as vaccines that protect against seasonal influenza. These vaccines leverage the companys virus-like particle (VLP) platform technology, Novasome adjuvants and unique production technology.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Novavax is focused on creating vaccines for a range of infectious diseases. The companys Estrasorb is the first topical emulsion for estrogen therapy approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause. The company also markets Gynodiol used for estrogen replacement therapy. The companys total revenues declined at a CAGR of 25% during 2002-2006, from $15 million to $5 million. The major reason for revenue decline was the decreasing product sales. Product sales of the company decreased at a CAGR of 34% during 2002-2006, from $13 million to $3 million. The companys total revenues would increase at a CAGR of 12% during 2006-2010 from $5 million to $8 million. The companys biggest contributor to revenue growth out to 2010 will be revenues from contract research and development.
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Novavax, Inc. - SWOT Analysis
Novavax, Inc. - Financial and Strategic Analysis Review
Novavax, Inc.
Novavax Inc-Therapeutic Competitors
NOVAVAX - World'Vest Base Dossier
Influenza VLP Vaccine Phase II trial Conference Call - Novavax, Inc., - Earnings Transcript
Novavax Inc-Detailed Product Pipeline
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
Human Vaccines - Global Strategic Business Report
Veterinary Vaccines - A World Market Analysis
Viropharma Incorporated: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Pipeline And Commercial Insight: Influenza Vaccines - Pandemic Threat Revitalizes The Sector
|
|
|
|
